13D Filings
Home
FAQ
Nautilus Biotechnology, Inc.
NAUT
Amendment
Ownership

10.00%

Total Shares

12,594,211

Issuer CIK

1808805

CUSIP

63909J108

Event Date

Jan 30, 2025

Accepted

Jan 31, 2025, 09:06 PM

SEC EDGARView Original Filing
Reporting Persons (3)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Perceptive Advisors LLC
Investment Adviser
10.00%12,594,211012,594,211
Joseph Edelman
Individual
10.00%12,594,211012,594,211
Perceptive Life Sciences Master Fund, Ltd.
CO
9.90%12,428,351012,428,351
Disclosure Items (2)

Security Title

Common Stock, par value $0.0001 per share

Issuer Name

Nautilus Biotechnology, Inc.

Issuer Address

2701 Eastlake Avenue, East Seattle, WA, 98102

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On January 28, 2025, Michael Altman, a Managing Director of Perceptive Advisors who has served on the Issuer's board of directors (the "Board") since June 2021, informed the Issuer that he will not stand for reelection to the Board at the Issuer's 2025 Annual Meeting of Stockholders (the "Annual Meeting"). Mr. Altman will remain a member of the Board until the conclusion of the Annual Meeting.